NO944838L - Arabinogalaktanderivater og anvendelser derav - Google Patents

Arabinogalaktanderivater og anvendelser derav

Info

Publication number
NO944838L
NO944838L NO944838A NO944838A NO944838L NO 944838 L NO944838 L NO 944838L NO 944838 A NO944838 A NO 944838A NO 944838 A NO944838 A NO 944838A NO 944838 L NO944838 L NO 944838L
Authority
NO
Norway
Prior art keywords
derivative
cell receptor
arabinogalactan
arabinogalactan derivatives
derivatives
Prior art date
Application number
NO944838A
Other languages
English (en)
Norwegian (no)
Other versions
NO944838D0 (no
Inventor
Chu Jung
Philip Enriques
Stephen Palmacci
Lee Josephson
Original Assignee
Advanced Magnetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Magnetics Inc filed Critical Advanced Magnetics Inc
Publication of NO944838D0 publication Critical patent/NO944838D0/no
Publication of NO944838L publication Critical patent/NO944838L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/605—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the macromolecule containing phosphorus in the main chain, e.g. poly-phosphazene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NO944838A 1992-06-17 1994-12-14 Arabinogalaktanderivater og anvendelser derav NO944838L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1992/005091 WO1993025239A1 (fr) 1992-06-17 1992-06-17 Derives d'arabinogalactane et leurs utilisations

Publications (2)

Publication Number Publication Date
NO944838D0 NO944838D0 (no) 1994-12-14
NO944838L true NO944838L (no) 1995-02-17

Family

ID=4154623

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944838A NO944838L (no) 1992-06-17 1994-12-14 Arabinogalaktanderivater og anvendelser derav

Country Status (5)

Country Link
EP (1) EP0646018A1 (fr)
JP (1) JPH07507794A (fr)
CA (1) CA2135295A1 (fr)
NO (1) NO944838L (fr)
WO (1) WO1993025239A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554386A (en) * 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
FR2716625B1 (fr) * 1994-02-25 1996-04-26 Gouchet Franck Arno Préparation et utilisation de formes pharmaceutiques et cosmétiques contenant des composés d'inclusion avec les cyclodextrines de cystéamine, sels de cystéamine, ou dérivés de la cystéamine, sous forme de sel ou non.
US5567685A (en) * 1994-08-16 1996-10-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Water-Soluble polyene conjugate
US5897987A (en) 1996-03-25 1999-04-27 Advanced Reproduction Technologies, Inc. Use of arabinogalactan in cell cryopreservation media
US6303584B1 (en) 1996-11-20 2001-10-16 The University Of Montana Water soluble lipidated arabinogalactan
US6011008A (en) * 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
CA2280997C (fr) 1997-03-11 2013-05-28 Perry B. Hackett Systeme transposon a base d'adn permettant d'introduire de l'acide nucleique dans l'adn d'une cellule
US6929936B1 (en) * 1997-07-18 2005-08-16 Danisco A/S Composition comprising an enzyme having galactose oxidase activity and use thereof
CA2330318A1 (fr) * 1998-04-27 1999-11-04 Larex, Inc. Derives de l'arabinogalactane et compositions les contenant
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
IL131074A0 (en) * 1999-07-23 2001-03-19 Polygene Ltd A biodegradable polycation composition for delivery of an anionic macromolecule
EP1286699A2 (fr) * 2000-05-19 2003-03-05 Regents Of The University Of Minnesota Composition pour l'introduction de composes dans des cellules
WO2003089618A2 (fr) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Systeme de transposons, et procedes d'utilisation
ITMI20040928A1 (it) 2004-05-07 2004-08-07 Uni Di Bologna Dipartiment O D Procedura per la preparazione di coniugati della doxorubicina con l'albumina umana lattosaminata
ITMI20051743A1 (it) * 2005-09-20 2007-03-21 Uni Di Bologna Dipartimento Di Patologia Spa Uso di coniugati della doxorubicina con albumina lattosaminata
RU2359975C2 (ru) * 2007-04-04 2009-06-27 Институт нефтехимии и катализа РАН Способ получения модифицированных арабиногалактанов
CN102399238B (zh) * 2011-12-21 2013-06-12 开封明仁药业有限公司 氨磷汀的制备方法
RU2521649C1 (ru) * 2013-03-04 2014-07-10 Федеральное Государственное Бюджетное Учреждение Науки Институт Химии И Химической Технологии Сибирского Отделения Российской Академии Наук (Иххт Со Ран) Способ получения сульфатированных производных арабиногалактана
WO2014176389A1 (fr) * 2013-04-24 2014-10-30 Temple University - Of The Commonwealth System Of Higher Education Forme pharmaceutique solide contenant de l'arabinogalactane

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3200766A1 (de) * 1981-01-14 1982-09-16 Toyo Jozo Kk Praeparat mit ausgezeichneter absorptionseigenschaft
JPH0816118B2 (ja) * 1988-02-03 1996-02-21 呉羽化学工業株式会社 抗ウイルス剤
JPH04501218A (ja) * 1988-08-04 1992-03-05 アドヴァンスド　マグネティックス　インコーポレーティッド 受容体媒介エンドサイト―シス型ｍｒｉ造影剤

Also Published As

Publication number Publication date
EP0646018A1 (fr) 1995-04-05
JPH07507794A (ja) 1995-08-31
WO1993025239A1 (fr) 1993-12-23
NO944838D0 (no) 1994-12-14
CA2135295A1 (fr) 1993-12-23

Similar Documents

Publication Publication Date Title
NO944838L (no) Arabinogalaktanderivater og anvendelser derav
NO985975L (no) Blandinger og fremgangsmÕter for frembringelse av farmakologisk aktive preparater og anvendelser derav
CA2083179A1 (fr) Isoxazole-4-carboxamides et hydroxyalkylidenecyanoacetamides; produits pharmaceutiques a base de ces composes et leur utilisation
DK0740650T3 (da) Codrugs som metode til styret transport af lægemiddel
PT804252E (pt) Agentes queladores metalicos que contem monoaminas diamidas e tiois
DK0655916T3 (da) Middel til transdermal administration indeholdende 3-ketodesogestrel
ATE219765T1 (de) Indolderivate als cgmp-pde inhibitoren
NO308794B1 (no) Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse
ES2180530T3 (es) Sulfonamidas de tiofeno utiles como inhibidores de anhidrasa carbonica.
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
AU5217493A (en) Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
HRP930239A2 (en) Anti-inflamatory 4-aminophenol derivatives
KR950700749A (ko) 2'-할로메틸리덴 유도체와 S-기 또는 M-기 특이성 항종양제를 사용하는 결합치료에 의한 암치료 방법(Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M phase specific antineoplastic agent)
AU2740797A (en) Androstene derivatives
DE69404116D1 (de) Mit Zucker überzogene pharmazeutische Dosierungseinheit
MX9706605A (es) Derivados de indol como antagonistas de los aminoacidos exitadores.
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
EP0971725A4 (fr) Procedes de traitement de tissu cicatriciel
GR3017967T3 (en) Substituted pyrido-oxazines.
ES2150400A6 (es) Una composicion para el tratamiento de desordenes ulcerosos del tracto gastrointestinal.
ES2119581A1 (es) Utilizacion de fragmentos de timosina y/o sus derivados
IT1265237B1 (it) Derivati basici dell'indolo
NO943795L (no) Metode for behandling av kreft ved konjunktiv terapi med 2'-halomethylidenderivater og et S-fase eller M-fase-spesifikt antineoplastisk middel
MX9800697A (es) Uso de glicosidos de calendula para el tratamiento de psoriasis.